Egg Donation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Egg donation (oocyte donation) is an assisted reproductive technology (ART) in which oocytes (eggs) retrieved from a healthy young donor are fertilised with sperm (from the recipient's partner or a sperm donor) in a laboratory to create embryos, which are then transferred to the recipient's uterus. It is the most effective fertility treatment for women who cannot use their own eggs — achieving live birth rates of 40–50% per cycle, substantially higher than IVF with autologous eggs in poor-prognosis patients.

Egg donation is the standard of care for: ovarian insufficiency (premature menopause or diminished ovarian reserve), women of advanced reproductive age (typically over 42–43 years), carriers of severe genetic conditions who are unsuitable to use their own eggs, women who have had failed multiple IVF cycles with own eggs, and women with absent or non-functional ovaries following cancer treatment or surgical menopause. It may also be used in same-sex male couples or single men in conjunction with surrogacy.

The egg donation process involves two parallel tracks: the donor undergoes controlled ovarian hyperstimulation (COS) with injectable gonadotropins for 10–14 days, followed by transvaginal ultrasound-guided oocyte retrieval under sedation; simultaneously (or on a synchronised schedule for fresh cycles, or independently for frozen donor egg cycles), the recipient's uterine lining (endometrium) is prepared with oestrogen and progesterone to optimise embryo implantation.

Egg donation is regulated differently across countries — fully legal with compensated donors in Spain, Czech Republic, Greece, and many US states; altruistic-only in the UK and Australia; prohibited in some countries. Medical tourism for egg donation, particularly to Spain, Czech Republic, and Cyprus, is substantial — an estimated 30,000–40,000 cycles per year involve cross-border treatment. India, previously a major destination, banned commercial egg donation to foreigners in 2018.

Egg donation is indicated for women with primary or premature ovarian insufficiency (POI/POF) — ovarian failure occurring before age 40, affecting approximately 1% of women, causing infertility and oestrogen deficiency. Women with diminished ovarian reserve (DOR) — defined by low antral follicle count (AFC below 5–7), elevated day-3 FSH (above 10–15 IU/L), and low AMH (below 0.5–1.0 ng/mL) — have poor response to ovarian stimulation with own eggs and significantly improved outcomes with donor eggs.

Women over 42–43 years have egg quantity and quality decline such that live birth rates with own eggs fall below 5–10% per cycle; donor egg IVF raises this to 40–50%. Women who carry X-linked or autosomal dominant genetic conditions with risk of transmission to offspring may choose egg donation to avoid preimplantation genetic testing (PGT) complexity or when PGT is not available. Turner syndrome (45,X) patients typically have no functional ovaries and require donor eggs for pregnancy. Cancer survivors with gonadal failure from chemotherapy or pelvic radiotherapy are a growing indication for egg donation.

Recipients must have a functional uterus capable of sustaining pregnancy. Evaluation includes uterine assessment (saline infusion sonography or hysteroscopy to exclude intracavitary fibroids, polyps, or adhesions), hormonal assessment (TSH, prolactin, uterine receptivity markers), and in women over 40, obstetric risk assessment for age-related pregnancy complications (hypertension, gestational diabetes, placenta praevia). Medical conditions affecting uterine function (severe Asherman syndrome, severe fibroids) require treatment before egg donation.

Egg donors are healthy women typically aged 20–35 years. Screening is comprehensive: medical history, gynaecological examination, ultrasound assessment of ovarian reserve (AFC ≥10–12), hormonal profile, comprehensive genetic carrier screening (cystic fibrosis, spinal muscular atrophy, chromosomal karyotype), infectious disease testing (HIV, hepatitis B/C, syphilis, HTLV, CMV), blood group, and psychological evaluation. Donors must have no personal or significant family history of heritable conditions. In many countries, anonymous donation is standard; in the UK, donors must be identifiable to resulting children at age 18.

Fresh donor egg cycle: Donor and recipient cycles are synchronised using GnRH agonist (leuprolide) or antagonist protocols to align ovulation timing with recipient endometrial preparation. Donor undergoes COS with recombinant FSH (150–300 IU/day) for 10–14 days with ultrasound and oestradiol monitoring. Final oocyte maturation is triggered with hCG or GnRH agonist when lead follicles reach 18–20 mm. Oocyte retrieval is performed 36 hours later under transvaginal ultrasound guidance with conscious sedation. Retrieved eggs are fertilised with prepared sperm by conventional insemination or ICSI.

Frozen donor egg cycle (vitrification): Donor eggs are cryopreserved after retrieval using vitrification (ultra-rapid freezing) and stored. Recipients can use frozen donor eggs in a synchronised cycle without the complexity of fresh cycle coordination. Vitrified eggs have survival rates of 80–90% after warming, with clinical outcomes comparable to fresh cycles. The majority of egg donation cycles in many countries now use frozen vitrified eggs from egg banks, providing flexibility in timing and greater donor availability.

Embryos are cultured to day 3 (cleavage) or day 5 (blastocyst). Blastocyst transfer is preferred as it allows selection of the strongest embryos. Single embryo transfer (SET) is recommended in most cases to minimise twin pregnancy risk. Preimplantation genetic testing for aneuploidy (PGT-A) may be added to select chromosomally normal embryos from donor egg batches, though the benefit is debated given already high euploid rates in young donors.

Egg donation offers the highest success rates of any fertility treatment for women with poor prognosis using own eggs. Clinical pregnancy rates per embryo transfer are 50–65%; live birth rates are 40–55% per transfer cycle — substantially higher than own-egg IVF in women over 40 (typically 5–15% per cycle). Cumulative live birth rates with multiple transfers from a single donation batch are 60–75% in many clinic reports.

Donor egg children are healthy and develop normally — numerous large studies confirm no increased risk of congenital malformations, developmental delay, or medical problems compared to naturally conceived children. The genetic relationship to the carrying mother is established through the intrauterine environment, maternal epigenetic influences, and breastfeeding, even without a genetic link. For many recipients, carrying a pregnancy and delivering the child remains profoundly meaningful despite the absence of genetic connection to the egg.

Ovarian stimulation success and egg yield are predictable with donors (typically 8–20 mature eggs retrieved from healthy young donors), and fresh or frozen embryo storage allows multiple attempts from a single donation. Psychological outcomes for recipients are generally positive — studies show high levels of relationship satisfaction, family functioning, and parental bonding in egg donation families.

Donor risks: Ovarian hyperstimulation syndrome (OHSS) is the most significant risk for donors — affecting 1–5% in moderate form and under 1% in severe form requiring hospitalisation. GnRH antagonist protocols and trigger modification (GnRH agonist trigger instead of hCG) have reduced severe OHSS substantially. Egg retrieval carries small risks of infection (0.1–0.3%), bleeding from follicle puncture wounds, and rare damage to adjacent structures. Long-term fertility effects of donation appear minimal in studies following donors for 10+ years.

Recipient risks include multiple pregnancy (significantly reduced with single embryo transfer policy), ectopic pregnancy (1–2%), and for older recipients, obstetric complications including hypertensive disorders of pregnancy (2–3x increased risk in women over 45), gestational diabetes, and peripartum cardiac complications in high-risk cases. Miscarriage risk in donor egg cycles is related to recipient age and uterine factors rather than egg quality, and is typically 15–20% overall. Psychological risks include adjustment to the non-genetic relationship to offspring, which benefits from specialist psychological counselling integrated into treatment.

Donors recover rapidly — typically returning to normal activities within 24–48 hours of egg retrieval. Mild pelvic discomfort, bloating, and spotting are expected for 2–5 days. A follow-up ultrasound at 5–7 days post-retrieval confirms ovarian recovery and excludes delayed OHSS. Donors are advised to avoid vigorous exercise until the next menstrual cycle to reduce torsion risk in still-enlarged ovaries.

Recipients begin progesterone supplementation (vaginal pessaries or intramuscular injections) on the day of egg retrieval (fresh cycle) or at least 5 days before transfer (frozen cycle). First pregnancy test via serum beta-hCG is performed 10–14 days after embryo transfer. Confirmed pregnancies continue progesterone supplementation until 10–12 weeks gestation when placental progesterone production is sufficient. Early pregnancy ultrasound at 6–7 weeks confirms intrauterine implantation, fetal cardiac activity, and number of embryos implanted. Ongoing obstetric care is transferred to the recipient's obstetrician with specialist consultation for high-risk aspects.

Egg donation IVF is one of the more expensive fertility treatments due to donor compensation, screening, stimulation medications, and coordination costs. In the United States, a fresh or frozen donor egg IVF cycle costs $25,000–$45,000 including agency fees, donor compensation ($5,000–$10,000), screening, medications, and clinic fees. Multiple cycles may be required, further increasing costs. Insurance coverage for egg donation is limited in most states.

Medical tourism for egg donation is substantial. Spain and the Czech Republic are the leading European destinations with costs of €4,000–€8,000 per cycle using vitrified donor eggs, inclusive of the egg batch, fertilisation, and embryo transfer — 60–80% less than US costs. Greece, Cyprus, and North Macedonia offer further cost advantages at €2,500–€4,500. These countries combine high clinic standards (many ESHRE-accredited), good regulatory frameworks, and internationally trained embryologists.

In Asia, Thailand, Malaysia, and some Indian clinics offer egg donation with overseas donors at $6,000–$12,000 per cycle. The cost advantage is real but regulatory frameworks and donor screening standards vary considerably — patients should carefully verify clinic accreditation, donor screening protocols, and regulatory compliance before travelling for treatment.

Embryo adoption (embryo donation) is an alternative where excess embryos from other couples' IVF cycles are donated and transferred to the recipient — providing both egg and sperm from donors. This is more cost-effective than egg donation in some countries but limits genetic connection to offspring from both sides. Adoption of existing children is an alternative pathway to parenthood that does not involve fertility treatment.

For women with diminished ovarian reserve rather than complete failure, own-egg IVF with ovarian stimulation may still be attempted — success rates are lower but genetic connection to offspring is preserved. Minimal stimulation IVF ('mini-IVF') and natural cycle IVF retrieve fewer eggs but expose to less stimulation hormones, useful for women with low AMH. Fertility preservation — freezing eggs or embryos at a younger age before ovarian reserve declines — is increasingly used for women at risk of premature ovarian insufficiency (e.g., before chemotherapy, women with BRCA mutations, Turner syndrome mosaics). Oophoropexy (ovarian transposition) before pelvic radiotherapy can preserve ovarian function in some cancer patients.